During the past decade, Mid Florida Hematology and Oncology Center conducted 40 clinical trials. In the 10-year time frame, 40 clinical trials started and 8 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 7 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mid Florida Hematology and Oncology Center" #1 sponsor was "Exact Sciences Corporation" with 4 trials, followed by "Novartis Pharmaceuticals" with 3 trials sponsored, "Amgen" with 2 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored and "Cogent Biosciences, Inc." with 2 trials sponsored. Other sponsors include 25 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mid Florida Hematology and Oncology Center" #1 collaborator was "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "Almac" with 1 trials as a collaborator, "George Clinical Pty Ltd" with 1 trials as a collaborator, "NSABP Foundation Inc" with 1 trials as a collaborator and "NeoGenomics" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Mid Florida Hematology and Oncology Center" are "Breast Cancer" (5 trials), "Colorectal Cancer" (3 trials), "Chemotherapy-induced Thrombocytopenia" (2 trials), "Lung Cancer" (2 trials) and "Melanoma" (2 trials). Many other conditions were trialed in "Mid Florida Hematology and Oncology Center" in a lesser frequency.

Most popular intervention types in "Mid Florida Hematology and Oncology Center" are "Drug" (34 trials), "Other" (6 trials), "Biological" (5 trials), "Combination Product" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (6 trials), "Placebo" (6 trials), "Blood Sample Collection" (3 trials), "Docetaxel" (3 trials) and "Pegfilgrastim" (3 trials). Other intervention names were less common.

The vast majority of trials in "Mid Florida Hematology and Oncology Center" are 39 trials for "All" genders, 2 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Mid Florida Hematology and Oncology Center". undefined are not yet recruiting, 15 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Mid Florida Hematology and Oncology Center, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Mid Florida Hematology and Oncology Center, 6 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

Mid Florida Hematology and Oncology Center has several departments that took part in Clinical trials: "Mid-Florida Hematology & Oncology Centers, PA" - 9 trials